Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]
, 2017 Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat +6 more
core +3 more sources
Human platelet activation by Escherichia coli: roles for FcγRIIA and integrin αIIbβ3 [PDF]
, 2016 Gram-negative Escherichia coli cause diseases such as sepsis and hemolytic uremic syndrome in which thrombotic disorders can be found. Direct platelet–bacterium interactions might contribute to some of these conditions; however, mechanisms of human ...
Arman, Mònica +5 more
core +3 more sources
Recreation of the terminal events in physiological integrin activation. [PDF]
, 2010 Increased affinity of integrins for the extracellular matrix (activation) regulates cell adhesion and migration, extracellular matrix assembly, and mechanotransduction.
Bobkov, Andrey A +8 more
core +3 more sources
Fibrin prestress due to platelet aggregation and contraction increases clot stiffness [PDF]
, 2021 Efficient hemorrhagic control is attained through the formation of strong and stable blood clots at the site of injury. Although it is known that platelet-driven contraction can dramatically influence clot stiffness, the underlying mechanisms by which ...
Eng, Wilson +3 more
core +2 more sources
Eptifibatide induced profound thrombocytopenia in a patient with pelvic malignancy: A case report [PDF]
, 2012 ► Eptifibatide is associated with profound thrombocytopenia and thrombosis secondary to a HITT-like mechanism associated with drug-dependant antibodies.
Guntupalli, Saketh R. +2 more
core +1 more source
Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization,secondary mediators, and Rac [PDF]
, 2010 The C-type lectin-like receptor 2 (CLEC-2)activates platelets through Src and Syk tyrosine kinases via a single cytoplasmic YxxL motif known as a hem immunoreceptor tyrosine-based activation motif (hemITAM).Here, we demonstrate using sucrose gradient ...
Alice Y. Pollitt +44 more
core +1 more source
Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route [PDF]
, 2011 Antiplatelet treatment in patients with an acute coronary syndrome (ACS), without or with ST segment elevation myocardial infarction (STEMI), forces to keep the balance between potential threats and optimal clinical advantages.
Michele Schiariti +2 more
core +2 more sources
Majalah Kardiologi Indonesia, 2013 Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of
Abdul Hakim Alkatiri +4 more
doaj +1 more source
How safe is eptifibatide during urgent carotid artery stenting?
Frontiers in Neurology, 2013 Background: Glycoprotein IIB/IIIA inhibitors are occasionally utilized during carotid artery stenting (CAS) in the presence or absence of a visualized intra-operative thrombus. Objective: We assess the hemorrhagic and clinical outcomes associated with
Hesham eAllam +7 more
doaj +1 more source
Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both? [PDF]
, 2006 The role of glycoprotein (Gp) IIb/IIIa receptor antagonists remains controversial and these agents are infrequently utilized during non-ST-segment elevation acute coronary syndromes (NSTE-ACS) despite American Heart Association/American College of ...
Donovan, Jennifer L +3 more
core +3 more sources